SIK2 and ovarian carcinoma: SIk2 inhibitor ARN-3261 enhances sensitivity to carboplatin of both carboplatin-sensitive and resistant ovarian cancer cells in vitro, inhibits tumor xenograft growth and enhances sensitivity to both carboplatin and paclitaxel in in vivo xenograft models.